Department of Pharmacy, COMSATS University Islamabad, Abbottabad, Pakistan.
Department of Pharmacy, University of Sargodha, Sargodha, Pakistan.
J Oncol Pharm Pract. 2021 Oct;27(7):1616-1622. doi: 10.1177/1078155220963212. Epub 2020 Oct 22.
Breast cancer patients use numerous medications, which include cytotoxic chemotherapy drugs, hormonal agents and supportive medication, so they are more vulnerable to potential adverse drug interactions. This study aimed to evaluate frequency, severity, clinical importance and risk factors responsible for the Drug-drug interactions (DDIs) in a cohort of patients suffering from breast cancer. Data was obtained from 150 patients in the oncology ward (both inpatient and outpatient) with a confirmed diagnosis of breast cancer and currently receiving standard breast cancer-directed treatment. The data was recorded into a pre-designed form specifically made for this study through individual patient interviews and by reviewing the detailed medical chart records of the patients. DDIs were identified by using drug interaction software such as Medscape mobile application and Micromedex version 2.The results of this study showed that all patients were female. The mean numbers of drugs that patients used were 7. Potential drug interactions were identified in 92% of the patients. When drug groups were overviewed, 32% of interactions were between anti neoplastic drugs, 62.9% interactions were between the anti neoplastic agent and supportive care drugs and 5% of them were between anti-cancer drugs and drugs used to treat comorbidities. Major DDIs were found in 62.2% of patients, 25.3% of DDIs were moderate and 12.4% were minor. The number of drugs, comorbid diseases, and selection of chemo protocols were the risk factors for drug interactions. Most of the DDIs found in breast cancer therapy may have adverse consequences on patient health and therapeutic outcomes. Therefore, health care professionals should review the medication regimen of patients with breast cancer before starting any chemotherapy treatment.
乳腺癌患者使用多种药物，包括细胞毒性化疗药物、激素制剂和支持性药物，因此更容易发生潜在的药物相互作用。本研究旨在评估患有乳腺癌的患者群体中药物-药物相互作用（DDI）的频率、严重程度、临床重要性和危险因素。从肿瘤科病房（住院和门诊）的 150 名确诊患有乳腺癌且正在接受标准乳腺癌定向治疗的患者中获得数据。通过对患者的个人访谈和详细的医疗记录回顾，将数据记录在专门为此研究设计的预定义表格中。使用药物相互作用软件（如 Medscape 移动应用程序和 Micromedex 版本 2）识别 DDI。本研究结果显示，所有患者均为女性。患者使用的药物平均数量为 7 种。在 92%的患者中发现了潜在的药物相互作用。当概述药物组时，32%的相互作用发生在抗肿瘤药物之间，62.9%的相互作用发生在抗肿瘤药物和支持性护理药物之间，5%的相互作用发生在抗癌药物和用于治疗合并症的药物之间。在 62.2%的患者中发现了主要的 DDI，25.3%的 DDI 为中度，12.4%为轻度。药物数量、合并症和化疗方案选择是药物相互作用的危险因素。在乳腺癌治疗中发现的大多数 DDI 可能对患者的健康和治疗结果产生不良后果。因此，医护人员在开始任何化疗治疗之前，应审查乳腺癌患者的药物治疗方案。
